Background. Most studies have reported that corticosteroid therapy adversely influences influenza-related outcomes.
Severe influenza is characterized by the induction of excessive production of proinflammatory cytokines [1, 2] . Inflammatory cytokines may suppress the hypothalamic-pituitary-adrenal axis, resulting in relative adrenal insufficiency, or compete with intracellular glucocorticoid receptor function, resulting in peripheral tissue steroid resistance [3] . Corticosteroids downregulate proinflammatory cytokine transcription and have been shown to improve innate immunity in patients with septic shock [4, 5] .
Based on theoretical considerations and evidence of benefit in severe sepsis, corticosteroids have been used inconsistently in the management of severe influenza and influenza-related acute respiratory distress syndrome (ARDS) [6] [7] [8] . During the 2009 influenza pandemic, 37%-55% of patients admitted to intensive care units (ICUs) in Europe received corticosteroids as part of their treatment [9] [10] [11] . Subsequent analysis of these cohorts found corticosteroids to be associated with no risk or an increased risk of mortality [9] [10] [11] . One randomized, controlled trial (RCT) of corticosteroids in ICU-admitted patients infected with 2009 pandemic influenza A virus subtype H1N1 (A[H1N1] pdm09) failed to recruit sufficient patients before the end of the pandemic [12] . An RCT of dexamethasone in avian influenza A(H5N1) infection also failed to recruit sufficient patients [13] . Considerable uncertainty remains regarding the impact of corticosteroids in the treatment of influenza.
We aimed to systematically review all experimental and observational studies assessing the effect of corticosteroids in the treatment of presumed influenza-associated complications on clinical outcomes, regardless of influenza virus subtype or clinical setting. The primary outcome measures were mortality and admission to an ICU.
METHODS
This systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. The study protocol was registered with the Cochrane Database of Systematic Reviews (http://onlinelibrary.wiley.com/doi/10.1002/14651858. CD010406/abstract).
Study Eligibility Criteria
RCTs, quasi-experimental designs, and observational studies assessing the association of systemic corticosteroids in the treatment of presumed influenza-associated complications on clinical outcomes were included. The intervention could be an intravenous or oral preparation of corticosteroid given for any clinical reason coinciding with influenza virus infection; there was no restriction on the dose or duration of intervention. Studies with <10 participants were excluded. We considered subjects of any age with clinically diagnosed influenza or influenza-like illness and/or with microbiologically confirmed influenza virus infection.
The primary outcome measures were 30-day mortality and rate of admission to ICUs. Secondary outcome measures were hospital readmission rate, length of stay, requirement for mechanical ventilation, and number and nature of adverse events attributable to corticosteroid use. [14] . The Scottish Intercollegiate Guidelines Network filter was used to identify observational studies. Core search terms relating to influenza (including "Influenzavirus A", "Influenzavirus B", and "influenza") and the exposure of interest, corticosteroid use (including "corticosteroid", "adrenocorticosteroid", "corticoid", "hydrocortisone", and"prednisolone"), were used. In addition, abstracts presented at 3 major international infectious diseases conferences (the Interscience Conference on Antimicrobial Agents and Chemotherapy, the European Society of Clinical Microbiology and Infectious Diseases, and Asia Pacific Society of Infection Control, from 2010 to March 2013), the bibliographies of included studies, and the Controlled Trials Registry (http://www.controlled-trials.com) were screened. Four domain experts were also individually contacted to identify relevant studies. Details of the literature search are shown in Supplementary Table 1 .
Search Strategy and Study Selection

Screening, Data Extraction, and Quality Assessment
Two authors (C. R. and W. S. L.) independently reviewed all citations retrieved. Study selection was performed in 2 stages: screening of study titles and abstracts, followed by scrutiny of the full text. Non-English-language articles were translated to English before screening. Disagreements at any stage were resolved through discussion with a third investigator (J. N.-V.-T.).
Data from included studies were independently extracted by 2 investigators, using a previously piloted pro forma (C. R. extracted data from all included studies; J. L. B., J. N.-V.-T., and W. S. L. each extracted data from one third of studies).
Two investigators (C. R. and J. L. B.) independently assessed the methodological quality of included studies at the outcome level, using the Cochrane Risk of bias tool and the NewcastleOttawa Scale (NOS) [14] . Differences in methodological quality assessment were resolved by referral to a third investigator (J. N.-V.-T.). The overall quality of evidence for the main outcome of interest was assessed using the Grading Assessment, Development, and Evaluation (GRADE) system [15] . Tables in which summaries of findings appear were constructed using GRADE profiler software, version 3.6.
Data Analysis
Dichotomous outcome data from individual studies were extracted as tabulated data, from which risk ratios (RRs) or odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. Adjusted outcome measures were extracted as ORs or hazard ratios (HRs) with 95% CIs and are presented separately in pooled analyses. For normally distributed continuous data, mean differences or standardized mean differences with corresponding 95% CIs were calculated. Medians and interquartile ranges were reported for continuous data that were not normally distributed.
Meta-analysis was performed using random-effects models. Heterogeneity was assessed using the I 2 statistic; when substantial (I 2 > 75%), data were not pooled for meta-analysis. Publication bias was assessed using funnel plots. Of the studies included in the meta-analysis of mortality, subgroup analysis was performed according to influenza virus subtype. All statistical analyses were performed in Review Manager, version 5.2 (Nordic Cochrane Centre and the Cochrane Collaboration, Copenhagen, Denmark).
RESULTS
Study Selection
The search identified 2668 articles. After removal of 604 duplicates, 2064 articles remained. Of these, 1996 were excluded after screening of titles and abstracts, and 52 were excluded after scrutiny of the full text ( Figure 1 ). The main reason for the exclusion of 52 articles was lack of relevant outcome data presented according to corticosteroid use. Of 16 articles included in the systematic review, 10 were included in the meta-analysis of mortality [9] [10] [11] [16] [17] [18] [19] [20] [21] [22] , while 6 were included in the narrative synthesis only; 3 investigated corticosteroid therapy before the diagnosis of influenza [23] [24] [25] , and 3 reported outcomes other than mortality according to corticosteroid use [26] [27] [28] .
Study Characteristics
The designs and characteristics of participants in included studies are summarized in Table 1 [9] [10] [11] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . All were observational designs. Outcome data according to corticosteroid use were reported for 3039 individuals. All studies were conducted, at least in part, within a hospital setting: 6 studies consisted only of individuals admitted to ICUs (1063 patients); 8 investigated admissions to both ICUs and hospital wards (1627 patients); 1 included individuals from non-ICU wards only (143 patients); and 1 investigated both outpatients and inpatients (206 patients). There were 13 studies of influenza A(H1N1)pdm09 (2652 patients), 2 of interpandemic (seasonal) influenza (349 patients), and 1 of avian influenza A(H5N1) (38 patients).
The median age of the cohort or corticosteroid treatment groups varied from 8 to 51 years (11 studies). Disease severity of patients at baseline was recorded according to corticosteroid therapy in 7 studies (1292 patients) [9-11, 16, 19, 21, 26] ; in 3 (543 patients), baseline disease severity was higher in the corticosteroid-treated group (Table 1) [11, 16, 21] .
Seven studies reported the doses or regimens of corticosteroid administered; the mean/median dose of corticosteroid therapy was 67.5-117.5 mg of prednisolone equivalent per day in 4 studies [10, 11, 16, 22] , and regimens of methylprednisolone 1-6 mg per kg per day were used in 3 studies [18, 19, 28] . The median duration of corticosteroid therapy varied from 5.1 to 11.0 days (4 studies). The risk of bias for 24 reported outcomes are summarized in Supplementary Table 2 . A maximum of 4 stars for the selection domain, 2 stars for the comparability domain, and 3 stars for the outcome domain (NOS) was achieved in 13 of 24, 6 of 24, and 21 of 24 reported outcomes in the included studies, respectively. Risk of bias specific to outcomes was greatest in the comparability domain, owing to inadequate adjustment for differences in baseline characteristics and disease severity.
Data Synthesis and Quantitative Analysis
The 13 studies of influenza A(H1N1) reported no difference or greater mortality associated with corticosteroid use. The single study of influenza A(H5N1) found that corticosteroid therapy was associated with increased mortality, following adjustment for neutropenia as a marker of disease severity [18] . Two studies of seasonal influenza failed to find any benefits associated with corticosteroid therapy [23, 25] . The inclusion criteria in these studies included any influenza-related hospital admission or ICU admission, severe respiratory failure (ARDS or requirement of mechanical ventilation), septic shock, multiorgan failure, or critical illness. However, it was not clear why some patients within these cohorts received systemic corticosteroid therapy and others did not. In particular, whether corticosteroid therapy was initiated primarily for treatment of unstable comorbid illnesses (including asthma and chronic obstructive pulmonary disease [COPD]) was not apparent.
Mortality
Because of heterogeneity in the reporting of timing of mortality from hospital admission, stratification by 30-day mortality was not possible. Therefore, mortality was considered as reported by individual studies (Table 2) . Meta-analysis of 10 studies (1497 patients) revealed a significantly higher odds of mortality with corticosteroid use (OR, 2.12; 95% CI, 1.36-3.29), with moderate statistical heterogeneity (I 2 = 40%; Figure 2 ). Subgroup analysis of 4 studies reporting adjusted ORs showed a similar association (OR, 2.82; 95% CI, 1.61-4.92) with very low heterogeneity (I 2 = 0%). Unadjusted mortality was not associated with corticosteroid use (OR, 1.74; 95% CI, .91-3.34; 6 studies); however, in a post hoc sensitivity analysis of unadjusted mortality estimates, excluding the single study that showed a trend toward benefit [20] , corticosteroid use was associated with a greater odds of mortality (OR, 2.02; 95% CI, 1.19-3.43), with moderate statistical heterogeneity (I 2 = 39%). There was no clear indication of publication bias revealed by funnel plot analysis of the 10 studies included in the meta-analysis. The quality of evidence specific to mortality was assessed as low by GRADE criteria (Supplementary Table 3 ). Two studies included in the meta-analysis also reported adjusted HRs for mortality associated with corticosteroid therapy; the first reported harm (HR, 2.59; 95% CI, 1.42-4.73) after adjustment for immunosuppression, disease severity (by Simplified Acute Physiology Score 3 criteria), and vasopressor use [10] , while the second found no significant association with mortality (HR, 1.06; 95% CI, .63-1.80) after adjustment for disease severity (by Acute Physiology and Chronic Health Evaluation II criteria) and comorbid illnesses [9] . These studies were not pooled because of high statistical heterogeneity (I 2 = 79%).
ICU Admission, Mechanical Ventilation, Length of Stay, and Nosocomial Infections
Studies reporting these outcomes are summarized in Tables 3  and 4 . Only 1 study reported adjusted estimates of effect; critical disease (defined as ≥1 of death, respiratory failure, septic shock, failure or insufficiency of ≥2 nonpulmonary organs, receipt of mechanical ventilation, or ICU admission) was associated with early corticosteroid use (≤72 hours), compared with late or no corticosteroid therapy, after adjustment for comorbid illnesses, age, pregnancy, and obesity (adjusted RR, 1.8; 95% CI, 1.2-2.8). Odds ratios (ORs) were determined by random-effects modeling. Abbreviations: CI, confidence interval; SE, standard error. Meta-analysis of individual outcomes could not be performed because of high statistical heterogeneity across studies.
Subgroup Analyses
Pooled subgroup analysis of 9 studies of influenza A(H1N1)pdm09 only found corticosteroid use to be associated with a greater odds of mortality (OR, 2.00; 95% CI, 1.26-3.16), with moderate statistical heterogeneity (I 2 = 42%).
Studies reporting outcomes according to different corticosteroid regimens are summarized in Table 5 . Outcomes stratified according to age groups (children vs adults) and route of corticosteroid administration (intravenous vs oral) were not reported in the studies included in this review.
Systemic Corticosteroid Use Before the Diagnosis of Influenza
A study of corticosteroid use for the treatment of graft-versushost disease in hematopoietic stem cell transplant recipients in the 2 weeks before the diagnosis of seasonal influenza found no observed differences in the time to death between individuals receiving low-dose corticosteroid therapy (<1 mg/kg/day of methylprednisolone; adjusted HR, 1.1; 95% CI, .4-3.6) and those receiving high-dose corticosteroid therapy (≥1 mg/kg/ day of methylprednisolone; adjusted HR, 1.1; 95% CI, .3-3.5), comparison with individuals receiving no prior corticosteroid therapy [23] . A mixed cohort of outpatients and inpatients with seasonal influenza reported an increased odds of "complicated influenza" (defined as the need for hospitalization due to pneumonia, neurological complications, invasive bacterial infection, myocarditis, or pericarditis) associated with corticosteroid therapy (adjusted OR, 12.19; 95% CI, 3.26-45.53; P = .0002) [25] .
In one study of individuals hospitalized with influenza A (H1N1)pdm09, corticosteroid therapy receipt ≤90 before hospital admission was independently associated with poor outcome (defined as a composite outcome of ICU admission and death; adjusted OR, 3.37, 95% CI, 1.39-8.20) [24] .
DISCUSSION
To our knowledge, this is the first systematic review and meta-analysis to investigate the influence of corticosteroids on clinically relevant outcomes in individuals with presumed influenza-associated complications, unrestricted by influenza virus subtypes. The main findings are as follows: (1) there were no completed RCTs, only observational studies, and (2) available data suggest that corticosteroid therapy is associated with a greater odds of mortality.
These findings must be viewed in the light of 2 important considerations. First, the indications for corticosteroid therapy were not fully specified in many studies. In some instances, the stated rationale was ARDS and septic shock [9, 10, 16, 22] . However, at one extreme, corticosteroid therapy may have been used as a last attempt in individuals with refractory illness. Conversely, they may have been used to treat less severe underlying Xi et al [22] Inhospital mortality, subjects, proportion: 9/30 vs 8/22; P = .854
Low-dose CS therapy defined as ≤80 mg methylprednisolone or equivalent daily dose; unadjusted outcome comorbid illnesses, such as exacerbations of asthma. The majority of studies included in this review relate to the 2009 pandemic, when revised guidance from the World Health Organization in February 2010 would have applied [29] . However, adherence to that guidance, which recommended that "patients who have severe or progressive clinical illness, including viral pneumonitis, respiratory failure, and ARDS due to influenza virus infection, should not be given systemic corticosteroids unless indicated for other reasons or as part of an approved research protocol" [30] is not known. Over the same period, the Surviving Sepsis Campaign recommended the use of corticosteroid therapy only in the setting of vasopressor-dependent septic shock [31] . The use of corticosteroids in the context of influenza virus infection but for different clinical indications (notably asthma) has been previously shown to be associated with different outcomes [32] ; this may reflect both the different mechanisms of action of corticosteroids depending on the underlying pathophysiology of the disease and the impact of bias by indication in reports from observational studies. This is compounded by the lack of consistent adjustment for disease severity across available studies.
The second consideration relates to the doses of corticosteroids used. These were poorly specified in many instances, and in cases when they were reported, a higher daily dose than typically recommended was used ( prednisolone equivalent ≤50 mg daily) for the treatment of septic shock or exacerbations of airways disease, such as asthma [31, 33] . Variability in corticosteroid dose and administration schedule are both factors associated with treatment outcomes in the setting of severe sepsis; in particular, high-doses given in short bursts have not been associated with benefit, compared with low doses given for longer durations (≥5 days) [34] . The use of higher doses of corticosteroids may explain the greater risk from secondary bacterial pneumonias due to Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa observed with corticosteroid therapy in some studies [16] .
The mechanisms behind potential harm from corticosteroids, aside from the risks from nosocomial infections, are not well defined. In patients with influenza A(H3N2) infection, systemic corticosteroid use for exacerbations of asthma or COPD was found to be associated with delayed viral clearance [35] . In turn, slower clearance of viral load was associated with mortality from ARDS in patients with influenza A(H1N1)pdm09 infection [36] . Although causation cannot be inferred from these studies, exposure to systemic corticosteroids without concurrent antiviral treatment, as was likely for some patients in the studies reviewed, may proffer the highest risk of harm [25, 27] .
A large (220-patient), multicenter, prospective cohort study of individuals admitted to ICUs across Europe with influenza A(H1N1) was not included in this review, owing to overlapping study populations. This study found no association between corticosteroid use at ICU admission and ICU mortality, after adjustment for age, comorbid illnesses, and disease severity (adjusted HR, 1.3, 95% CI, .7-2.4; P = .4) [7] . The estimates of mortality in this review are also in contrast to the evidence base from clinical trials of corticosteroids in the setting of other severe infections. Specifically, in a meta-analysis of 17 RCTs (involving 2138 patients) of corticosteroids in severe sepsis, subgroup analysis found that prolonged low-dose corticosteroid therapy was associated with lower 28-day mortality [34] ; and in a metaanalysis of 9 RCTs (involving 1001 patients) of adults with community-acquired pneumonia (CAP), subgroup analysis of severe CAP revealed a survival benefit associated with corticosteroids [37] . Larger trials of corticosteroid therapy in severe CAP are currently in progress and should provide more-robust data within the next few years [38] [39] [40] . In the setting of ICUacquired pneumonia, a prospective cohort study of 316 patients found higher 28-day mortality with corticosteroid treatment in a propensity-score-adjusted analysis [41] .
For this systematic review, no restrictions were placed on the demographic characteristics of included participants, study settings, or influenza virus subtypes. However, the available evidence identified consisted solely of observational data. A high degree of correlation between corticosteroid therapy and potential confounders for measured outcomes (such as disease severity and the presence of comorbid illness) was noted in some studies; thus, unadjusted effect estimates are likely to be confounded by indication [11, 16, 21, 22] . Other important variables associated with influenza-related mortality, including time to hospitalization, use and time to initiation of antiviral therapy, and presence of respiratory failure at commencement of corticosteroid therapy, were inconsistently reported in the included studies. The pooled analysis of mortality showed moderate statistical heterogeneity, which may have been due to the inclusion of unadjusted estimates of mortality and to a single outlying study demonstrating a trend toward benefit related to corticosteroid therapy [20] . Clinical heterogeneity was apparent across included studies. Specifically, disease severity was measured using a wide variety of clinical risk scores, and mortality was reported at different time points; the rationale for corticosteroid use was inconsistent across studies; there was variation in the treatment groups with regard to the timing, dosage, duration, and type of corticosteroid used; and the cointerventions for the control groups across studies were not uniform as varying proportions of adults were treated with antivirals and/or antibiotics.
This systematic review highlights that a firm conclusion regarding the value of corticosteroid therapy for influenza cannot be drawn from the current evidence base alone. The lack of sufficient data on the indications for corticosteroid therapy and the differing dosing schedules adopted were major limitations, given the importance of these factors on the therapeutic potential of corticosteroids. There is a clear need for more-robust evidence through the conduct of well-designed RCTs on the role of corticosteroids, particularly at low doses; relevant groups of patients that should be tested include severely ill patients with complications of influenza, including primary viral pneumonia, ARDS, and septic shock. Less pressing is the need for trials in nonseverely ill patients with influenza-related exacerbations of underlying obstructive airway diseases, such as asthma and COPD. In the meantime, the findings from this review support the existing recommendations from the World Health Organization that corticosteroids should not be used in the treatment of influenza virus infection unless indicated for other reasons, such as vasopressor-dependent septic shock, or as part of an approved research protocol.
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